These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 28793974

  • 1. Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.
    Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS.
    Biol Psychiatry; 2017 Dec 15; 82(12):866-874. PubMed ID: 28793974
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder.
    Hodgins GE, Blommel JG, Dunlop BW, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Harvey PD.
    J Clin Psychopharmacol; 2018 Jun 15; 38(3):200-206. PubMed ID: 29505471
    [Abstract] [Full Text] [Related]

  • 5. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.
    Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, Heilig M.
    Neuropsychopharmacology; 2016 Nov 15; 41(12):2818-2829. PubMed ID: 27109623
    [Abstract] [Full Text] [Related]

  • 6. Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.
    Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht SS, Neylan TC, Mathew SJ, Iosifescu D, Rothbaum BO, Mayberg HS, Dunlop BW.
    Psychophysiology; 2020 Jan 15; 57(1):e13356. PubMed ID: 30807663
    [Abstract] [Full Text] [Related]

  • 7. The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.
    Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M.
    Neuropsychopharmacology; 2015 Mar 13; 40(5):1064-71. PubMed ID: 25430779
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
    Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.
    Depress Anxiety; 2010 May 13; 27(5):417-25. PubMed ID: 20455246
    [Abstract] [Full Text] [Related]

  • 10. Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
    Turcu AF, Spencer-Segal JL, Farber RH, Luo R, Grigoriadis DE, Ramm CA, Madrigal D, Muth T, O'Brien CF, Auchus RJ.
    J Clin Endocrinol Metab; 2016 Mar 13; 101(3):1174-80. PubMed ID: 26751191
    [Abstract] [Full Text] [Related]

  • 11. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y.
    Encephale; 2012 Oct 13; 38(5):373-80. PubMed ID: 23062450
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
    Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM.
    J Clin Psychiatry; 2011 Jul 13; 72(7):892-7. PubMed ID: 21367352
    [Abstract] [Full Text] [Related]

  • 14. Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder.
    Rasmusson AM, Lipschitz DS, Wang S, Hu S, Vojvoda D, Bremner JD, Southwick SM, Charney DS.
    Biol Psychiatry; 2001 Dec 15; 50(12):965-77. PubMed ID: 11750893
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of early adolescent stress: dysregulation of hypothalamic-pituitary-adrenal axis and central corticotropin releasing factor receptor 1 expression in adult male rats.
    Li C, Liu Y, Yin S, Lu C, Liu D, Jiang H, Pan F.
    Behav Brain Res; 2015 Jul 15; 288():39-49. PubMed ID: 25882722
    [Abstract] [Full Text] [Related]

  • 16. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse.
    Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W.
    Biol Psychiatry; 2002 Dec 01; 52(11):1102-12. PubMed ID: 12460693
    [Abstract] [Full Text] [Related]

  • 17. Effects of oxytocin on prosocial behavior and the associated profiles of oxytocinergic and corticotropin-releasing hormone receptors in a rodent model of posttraumatic stress disorder.
    Wang SC, Lin CC, Tzeng NS, Tung CS, Liu YP.
    J Biomed Sci; 2019 Mar 21; 26(1):26. PubMed ID: 30898126
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genetics of glucocorticoid regulation and posttraumatic stress disorder--What do we know?
    Castro-Vale I, van Rossum EF, Machado JC, Mota-Cardoso R, Carvalho D.
    Neurosci Biobehav Rev; 2016 Apr 21; 63():143-57. PubMed ID: 26872620
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.